-
Your selected country is
France
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Immunohistochemical staining for c-erbB-2. Formalin-fixed, paraffin-embedded tissue section of human breast cancer stained with Anti-Human c-ErbB-2 (clone 3B5, Cat. No. 554299) using a DAB chromogen and Hematoxylin counterstain.
BD Pharmingen™ Purified Mouse Anti-Human c-ErbB-2
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
Applications include immunoprecipitation (1-2 µg/one million cells), western blot analysis (1-2 µg/ml), and immunohistochemistry of frozen and formalin-fixed paraffin-embedded tissue sections (5-20 µg/ml). Positive control cell lines include MCF7 cells (ATCC HTB 22) and SK-BR-3 (ATCC HTB 30) human breast carcinoma cells.
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
C-erbB-2 (also known as HER2/neu), a 185 kDa transmembrane glycoprotein, is a member of the type 1 growth factor receptor subfamily which also includes c-erbB-3, c-erbB-4 and the epidermal growth factor receptor (EGFR), also known as c-erbB-1. Members of this receptor subfamily mediate the proliferation and differentiation of normal cells. They have a common structure consisting of an extracellular domain, a transmembrane region, and a cytoplasmic sequence. The extracellular regions contain two cysteine-rich domains, and the intracellular regions have sequence homology to known tyrosine kinases. C-erbB-2 reactivity has been detected in proximal kidney tubules, mucosal epithelium in the gastrointestinal tract, and squamous epithelium in skin. Most normal adult tissues show little or no reactivity with antibodies against c-erbB-2. However, c-erbB-2 is overexpressed in many human breast, stomach, ovary and bladder carcinomas. EGFR, c-erbB-3 and c-erbB-4 are also overexpressed in various human tumor cells, and it is thought that aberrant activation of type 1 growth factor kinase activities may contribute to tumor progression.
The antibody 3B5 recognizes human c-erbB-2. A synthetic peptide corresponding to amino acids 1242-1255 (TAENPEYLGLDVPV) in the C-terminal domain of human c-erbB-2 was used as immunogen.
Development References (10)
-
Carraway KL 3rd, Cantley LC. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell. 1994; 78(1):5-8. (Biology). View Reference
-
Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991; 51(17):4575-4589. (Biology). View Reference
-
In: Hesketh R. The Oncogene Handbook. New York: Academic Press; 1994:485-509.
-
Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study. Pathologica. 1993; 85(1100):637-644. (Clone-specific: Immunohistochemistry). View Reference
-
Meissner K, Riviere A, Haupt G, Loning T. Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. Am J Pathol. 1990; 137(6):1305-1309. (Clone-specific: Immunohistochemistry). View Reference
-
Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994; 173(1):65-75. (Clone-specific: Immunohistochemistry). View Reference
-
Schwechheimer K, Laufle RM, Schmahl W, Knodlseder M, Fischer H, Hofler H. Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol. 1994; 25(8):772-780. (Clone-specific: Immunohistochemistry). View Reference
-
Singleton TP, Niehans GA, Gu F, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol. 1992; 23(10):1141-1150. (Clone-specific: Immunohistochemistry). View Reference
-
Zhau HE, Zhang X, von Eschenbach AC, et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog. 1990; 3(5):254-257. (Clone-specific: Immunohistochemistry, Western blot). View Reference
-
van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988; 319(19):1239-1245. (Clone-specific: Immunohistochemistry, Immunoprecipitation). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.